Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baricitinib - Eli Lilly/Incyte Corporation

Drug Profile

Baricitinib - Eli Lilly/Incyte Corporation

Alternative Names: INCB-028050; INCB-28050; LY-3009104; Olumiant

Latest Information Update: 06 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Incyte Corporation
  • Class Acetonitriles; Antipsoriatics; Antirheumatics; Azetidines; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Uroprotectives
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase III Atopic dermatitis; Juvenile rheumatoid arthritis; Systemic lupus erythematosus
  • Phase II/III Alopecia areata
  • Phase II Giant cell arteritis
  • Clinical Phase Unknown Psoriatic arthritis
  • Preclinical Primary biliary cirrhosis
  • Discontinued Diabetic nephropathies; Psoriasis

Most Recent Events

  • 05 Feb 2019 Topline adverse events data from the phase-III BREEZE-AD1 and BREEZE-AD2 trial in Atopic dermatitis released by Eli Lilly
  • 17 Dec 2018 Phase-III clinical trials in Juvenile rheumatoid arthritis (In children, In adolescents, Treatment-experienced) in Japan (PO) (NCT03773978)
  • 17 Dec 2018 Eli Lilly and Company plans the JUVE-BASIS phase III trial for Juvenile Idiopathic Arthritis in Brazil, Germany, Japan, Mexico and Russia , (NCT03773978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top